Stem Cells, Vol 12, 322-328, Copyright © 1994 by AlphaMed Press
In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial
C Fossat, AM Stoppa, D Sainty, D Blaise, P Viens, M Bayssas, A Yver, I Juhan- Vague and D Maraninchi
Laboratoire d'Hematologie, Hopital de la Timone, Marseille, France.
The aim of this work was to study the evolution of neutrophil functions in
non-neutropenic cancer patients. Thirty non-neutropenic patients, median
age 35 years (range 19-52), with solid tumors (n = 21) or lymphomas (n = 9)
entered a phase I study of five days of s.c. (n = 24) or i.v. bolus (n = 6)
lenograstim, recombinant human glycosylated granulocyte colony-stimulating
factor (rHuG-CSF Chugai-Rhone-Poulenc), with dose escalation from 1 to 40
micrograms/kg/day. Neutrophil functions were studied before lenograstim
(D1) and 24 h after the last dose (D6). Granulocyte count rose in a
significant way, and enzyme release, phagocytosis and bacterial killing
were stimulated. All patients had improvement of at least one neutrophil
function. Directed migration was depressed, although it was still in the
normal range. These findings confirm that lenograstim is a potent activator
of neutrophil functions in non-neutropenic cancer patients and may be
useful as an adjunct to conventional antimicrobial therapy.
